Stocks Health care TMDX
NASDAQ · Health careTransMedics Group, Inc. (TMDX)
TransMedics Group, Inc. brought in $727.7M of revenue over the twelve months to September 30, 2026, up 28.5% from a year earlier. Net income was $144.5M, a net margin of 19.9%. Operating cash flow minus capital spending left $133.6M of free cash flow in fiscal 2025. At September 30, 2026 it held $511.4M in cash against $54.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about TransMedics Group, Inc.
- Net worth
- TransMedics Group, Inc. has a market value (market cap) of $3.2B at the latest share price, and shareholders' equity of $550.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $605.5M (+37.1% year on year), with net income of $190.3M. Over the 12 months to September 30, 2026: revenue $727.7M, net income $144.5M.
- Cash flow
- In fiscal 2025 operations brought in $192.8M of cash; after $59.3M of capital spending, free cash flow was $133.6M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- TransMedics Group, Inc.'s next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What TransMedics Group, Inc. does
TransMedics Group, Inc. is registered with the SEC under industry code SIC 3845 (Electromedical & Electrotherapeutic Apparatus). Its shares trade on NASDAQ under the ticker TMDX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $605.5M | $190.3M | $4.87 | $133.6M |
| 2024 | $441.5M | $35.5M | $1.01 | -$80.9M |
| 2023 | $241.6M | -$25M | -$0.77 | -$164.9M |
| 2022 | $93.5M | -$36.2M | -$1.23 | -$57.7M |
| 2021 | $31.4M | -$44.2M | -$1.60 | -$32.4M |
| 2020 | $28.4M | -$28.7M | -$1.16 | -$30.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TMDX ranks in Health care
Latest SEC filings
What TransMedics Group, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 41% to $203M versus the same quarter last year; diluted EPS $0.46 versus $0.66.
- November 5, 2026
- September 10, 2026
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 21% to $189.9M versus the same quarter last year; diluted EPS $0.41 versus $0.92.
- August 4, 2026
- May 29, 2026
- May 21, 2026
- May 7, 2026Additional proxy material DEFA14A
- May 5, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 21% to $173.9M versus the same quarter last year; diluted EPS $0.20 versus $0.70.
- May 5, 2026
What is TMDX worth? A DCF from its reported cash flow
Insider trades
What the people running TransMedics Group, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $109.1K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 28, 2026 | Araujo Fernando N.See Remarks | Received as pay | 22,969 | - |
| September 11, 2026 | Weill DavidDirector | Bought | 1,336 | $109.1K |
| August 17, 2026 | Tobin James RDirector | Gave as a giftindirect | 18,000 | - |
| July 10, 2026 | Hassanein Waleed HPresident & CEO, Director | Received as pay | 49,669 | - |
| July 10, 2026 | Hernandez GerardoChief Financial Officer | Received as pay | 17,246 | - |
| July 10, 2026 | Corcoran NicholasSee remarks | Received as pay | 11,727 | - |
| June 15, 2026 | Gunderson Thomas J.Director | Exercised options | 19,285 | $42.6K |
| June 15, 2026 | Gunderson Thomas J.Director | Sold | 9,624 | $722.4K |
Who owns TMDX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 15% | May 12, 2025 |
| Vanguard Portfolio Management13G, passive | 5.68% | April 29, 2026 |
| Vanguard Capital Management13G, passive | 5.06% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 374 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 5,596,549 | +303,218 |
| Fmr LLC | 5,133,328 | +37,085 |
| Vanguard Portfolio Management LLC | 1,933,989 | +14,454 |
| Vanguard Capital Management LLC | 1,497,600 | +19,448 |
| State Street Corp | 1,420,421 | +100,942 |
| Nomura Asset Management International Inc. | 910,495 | +24,654 |
| Geode Capital Management, LLC | 894,913 | +55,758 |
| Hood River Capital Management LLC | 751,133 | +51,363 |
| Dimensional Fund Advisors LP | 610,107 | +93,428 |
| Braidwell LP | 609,715 | +280,324 |
| Goldman Sachs Group Inc | 559,771 | -306,511 |
| Citadel Advisors LLC | 558,824 | +497,223 |
| Eventide Asset Management, LLC | 548,874 | +50 |
| Wellington Management Group Llp | 515,973 | +29,500 |
| Emerald Advisers, LLC | 490,491 | +147,700 |
| UBS Group AG | 488,058 | -92,735 |
| Morgan Stanley | 405,112 | -289,038 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 398,250 | -541,273 |
| Invesco Ltd. | 394,979 | -642,995 |
| Citigroup Inc | 386,066 | +28,685 |
Insiders
14 insiders reported holding 1,132,425 shares in total, about $103M at the last price.
| Holder | Shares |
|---|---|
| Hassanein Waleed HPresident & CEO, Director | 666,102495,009 held indirectly |
| Kania EdwinDirector | 263,732 |
| Corcoran NicholasSee remarks | 41,558 |
| Hernandez GerardoChief Financial Officer | 31,935 |
| Araujo Fernando N.See Remarks | 22,969 |
| Cecere GiovanniChief Commercial Officer | 19,057 |
| Gunderson Thomas J.Director | 16,642 |
| Weill DavidDirector | 16,392 |
| Forsyth Matthew S.See Remarks | 15,409 |
| Ranganath Anil P.See remarks | 13,091 |
Questions about TMDX
What does TransMedics Group, Inc. do?
TransMedics Group, Inc. is a company in the Health care sector, listed on NASDAQ as TMDX. Its shares trade on NASDAQ under the ticker TMDX.
What is TransMedics Group, Inc.'s net worth?
TransMedics Group, Inc. has a market value (market cap) of $3.2B at the latest share price, and shareholders' equity of $550.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is TransMedics Group, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $144.5M on revenue of $727.7M, a net margin of 19.9%.
How much revenue does TransMedics Group, Inc. make?
Over the twelve months to September 30, 2026 TransMedics Group, Inc. reported revenue of $727.7M. That is 28.5% more than a year earlier.
When did TransMedics Group, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the planned insider sale from November 9, 2026.
When is TransMedics Group, Inc.'s next earnings report?
TransMedics Group, Inc.'s next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TMDX with
Follow TMDX
Get an email when TransMedics Group, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values TransMedics Group, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.